Cost-effectiveness analysis using a Markov model assessing the addition of bevacizumab to paclitaxel in HER-2-negative metastatic breast cancer patients - Refaat, T; Choi, M; Gaber, G (J Clin Oncol, 2012)
Abstr. 1069